Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

Summary

This randomized phase II trial studies how well docosahexaenoic acid works in preventing recurrence in breast cancer survivors. Docosahexaenoic acid supplement may prevent recurrence in breast cancer survivors.

Timeline

Start

2013-05

Primary completion

2016-01-11

Completion

2020-04-22

Outcome

Missed primary endpoint

registry analysis (superiority test); Placebo; p = .50; ANCOVA NCT01849250 ↗

Drugs

Indications